TGTX vs. RYTM

Last updated Apr 1, 2026

Compare and contrast key facts about TG Therapeutics, Inc. (TGTX) and Rhythm Pharmaceuticals, Inc. (RYTM).

Performance

TGTX vs. RYTM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TG Therapeutics, Inc. (TGTX) and Rhythm Pharmaceuticals, Inc. (RYTM). The values are adjusted to include any dividend payments, if applicable.

TGTX vs. RYTM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
TGTX TG Therapeutics, Inc.	11.44%	-0.96%	76.23%	44.38%	-37.74%	-63.48%	368.65%	170.73%	-50.00%	-33.06%
RYTM Rhythm Pharmaceuticals, Inc.	-18.75%	91.21%	21.78%	57.86%	191.78%	-66.43%	29.49%	-14.58%	-7.50%	-3.13%

Fundamentals

EPS TGTX : $2.77 RYTM : -$3.11
PS Ratio TGTX : 10.10 RYTM : 29.78
Total Revenue (TTM) TGTX : $531.90M RYTM : $189.76M
Gross Profit (TTM) TGTX : $453.87M RYTM : $170.27M
EBITDA (TTM) TGTX : $115.24M RYTM : -$178.54M

Returns By Period

In the year-to-date period, TGTX achieves a 11.44% return, which is significantly higher than RYTM's -18.75% return.

TGTX

• 1D: 5.43%
• 1M: 10.40%
• YTD: 11.44%
• 6M: -8.04%
• 1Y: -15.75%
• 3Y*: 30.23%
• 5Y*: -7.46%
• 10Y*: 14.00%

RYTM

• 1D: 12.58%
• 1M: -6.21%
• YTD: -18.75%
• 6M: -13.88%
• 1Y: 64.19%
• 3Y*: 69.56%
• 5Y*: 31.36%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TGTX vs. RYTM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TGTX

TGTX Risk / Return Rank: 28
TGTX Sharpe Ratio Rank: 26
TGTX Sortino Ratio Rank: 26
TGTX Omega Ratio Rank: 26
TGTX Calmar Ratio Rank: 29
TGTX Martin Ratio Rank: 33

RYTM

RYTM Risk / Return Rank: 77
RYTM Sharpe Ratio Rank: 76
RYTM Sortino Ratio Rank: 81
RYTM Omega Ratio Rank: 75
RYTM Calmar Ratio Rank: 73
RYTM Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TGTX vs. RYTM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TG Therapeutics, Inc. (TGTX) and Rhythm Pharmaceuticals, Inc. (RYTM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TGTX	RYTM	Difference
Sharpe ratio Return per unit of total volatility	-0.34	1.06	-1.40
Sortino ratio Return per unit of downside risk	-0.18	2.13	-2.31
Omega ratio Gain probability vs. loss probability	0.98	1.25	-0.27
Calmar ratio Return relative to maximum drawdown	-0.40	1.65	-2.05
Martin ratio Return relative to average drawdown	-0.60	5.55	-6.15
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TGTX vs. RYTM - Sharpe Ratio Comparison

The current TGTX Sharpe Ratio is -0.34, which is lower than the RYTM Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of TGTX and RYTM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TGTX	RYTM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.34	1.06	-1.40
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.09	0.41	-0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.16	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	0.19	-0.24

Correlation

The correlation between TGTX and RYTM is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TGTX vs. RYTM - Dividend Comparison

Neither TGTX nor RYTM has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

TGTX vs. RYTM - Drawdown Comparison

The maximum TGTX drawdown since its inception was -99.52%, which is greater than RYTM's maximum drawdown of -92.10%. Use the drawdown chart below to compare losses from any high point for TGTX and RYTM.

Drawdown Indicators

	TGTX	RYTM	Difference
Max Drawdown Largest peak-to-trough decline	-99.52%	-92.10%	-7.42%
Max Drawdown (1Y) Largest decline over 1 year	-42.01%	-35.54%	-6.47%
Max Drawdown (5Y) Largest decline over 5 years	-92.36%	-86.16%	-6.20%
Max Drawdown (10Y) Largest decline over 10 years	-93.19%	—	—
Current Drawdown Current decline from peak	-85.77%	-26.06%	-59.71%
Average Drawdown Average peak-to-trough decline	-91.55%	-32.33%	-59.22%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.97%	10.58%	+17.39%

Volatility

TGTX vs. RYTM - Volatility Comparison

The current volatility for TG Therapeutics, Inc. (TGTX) is 15.21%, while Rhythm Pharmaceuticals, Inc. (RYTM) has a volatility of 19.66%. This indicates that TGTX experiences smaller price fluctuations and is considered to be less risky than RYTM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TGTX	RYTM	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.21%	19.66%	-4.45%
Volatility (6M) Calculated over the trailing 6-month period	28.18%	36.17%	-7.99%
Volatility (1Y) Calculated over the trailing 1-year period	46.37%	60.78%	-14.41%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	87.52%	76.51%	+11.01%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	86.94%	71.45%	+15.49%

Financials